

Charity Registration No. 285946

Company Registration No. 493724 (England and Wales)

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Dr Zaloa Agirre-Arrizubieta
Professor Mark Baker
Dr Natalie Ross
Dr Sushma Goyal
Dr Brython Hywel
Dr Stephan Jaiser
Dr Samantha Jefferson
Professor Martin Koltzenburg
Dr Andrew Michell
Dr Friederike Moeller
Dr Gareth Payne
Dr Ronit Pressler
Dr Syed Shah
Dr Rachel Thornton
Dr Simon Freilich (Appointed 6 October 2023)
Dr Jiten Mistry (Appointed 6 October 2023)

Charity number

285946

Company number

493724

Independent examiner

Katherine Dee FCA ACA
Begbies Chartered Accountants
9 Bonhill Street
London
EC2A 4DJ

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

CONTENTS

	Page
Trustees' report	1 - 3
Independent examiner's report	4
Statement of financial activities	5 - 6
Summary income and expenditure account	7
Balance sheet	8
Notes to the financial statements	9 - 19

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 30 JUNE 2024

The trustees of The British Society for Clinical Neurophysiology (BSCN) present their report and accounts for the year ended 30 June 2024 and confirm that they comply with current statutory requirements and with the requirements of the Society's governing instrument.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charitable company's [governing document], the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The charitable company's objects are to promote and assist the science and practice of electroencephalography, clinical neurophysiology and allied subjects.

The policies adopted in furtherance of these objects are as following and there has been no change in these during the year:

1. To organise scientific meetings of the Society (usually 2-3 per year)
2. To organise teaching courses (triennial)
3. To organise essay prizes in the subject
4. To provide an Annual Medical Student Bursary, of up to £5,000, in support of a Neurosciences BSc.

The trustees consider they have complied with the duty of section 17(5) of the Charities Act 2011, having paid due regard to public benefit guidance issued by the Charity Commission in deciding what activities the charitable company should undertake.

Achievements and performance

Having embraced the technological challenges of running our scientific meetings virtually, out of necessity during the COVID-19 pandemic, the Society has continued to provide a virtual offering. This continues to be popular with the membership, increasing the accessibility to continuing professional development while reducing the need for travel. Both our Autumn meeting in 2023, hosted by the Fetal Medicine Research Institute, London, and Spring Meeting held at the University of Edinburgh were run as hybrid events. All meetings were well attended and the feedback has been good.

In June 2023, we learned at the European Congress of Clinical Neurophysiology (ECCN) meeting in Marseille that the Society had been successful in its bid to host the 2025 ECCN meeting in London. An independent company has been established to organise and administer the ECCN 2025 meeting and thus the Society will be protected from any financial liability. Planning for the event is ongoing.

The BSCN would normally have expected to organise the triennial Oxford teaching course for Spring 2025. However, because the ECCN 2025 meeting will include comparable teaching opportunities to those planned for the Oxford course, a decision was made by Council to postpone the Oxford teaching course for 2025.

The BSCN continues to honour achievement in clinical neurophysiology, and award prizes and grants. The total cost of awards for the 2023/4 year was £7,620.

The Medical Student Essay Prize of £500 which was awarded to Zekai Qiang from Sheffield University.

The Adrian Prize of £1000 was awarded to Rohan Kandasamy from the National Hospital for Neurology and Neurosurgery.

The undergraduate bursary of £5,000 was awarded to Alana Hodgson from Sheffield University.

Book bursaries totalling £1,199 were awarded to eight recipients.

General bursaries totalling £7,000 were awarded to fourteen UK trainees in clinical neurophysiology, providing financial assistance to enable the recipients to attend training courses in neonatal EEG and paediatric EMG.

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 30 JUNE 2024

Subscriptions

Income from membership subscriptions decreased by 6.6% during the year to 30th June 2024.

Meetings

Expenses relating to Society meetings amounted to £22,273, and income amounted to £37,203.

These costs are directly attributable to the meetings, and are before the share of governance or support costs.

Professional fees

Independent Examination for the year were £3,133.

Investments

The market value of the Society's investments decreased during the year by £5,200 (6.2%). These investments produced dividends and gross interest of £4,488.

Financial review

The Society's financial position remains very sound. This year the Society reports a net surplus for the year of £13,882; however, the Society always aims to break even year on year and leave sufficient funds in order to fund the running of large events, including future triennial teaching courses in Oxford. After the success of the Society's bid to host the ECCN in 2025, we have been working on the ECCN 2025 budget with a professional conference organiser (PCO), who have set up a limited company, with Dr Nick Kane and Dr Jacquie Deeb as Directors. This will ensure that the Society does not have any financial liability for ECCN 2025 and will not be expected to underwrite the congress. However, given the ECCN will take place instead of the triennial course in 2025, the Society will provide support for the ECCN, as it has previously for the triennial course.

Reserves policy

The Society holds reserves sufficient to underwrite any potential losses in respect of the next triennial teaching course. At the year end the reserves stood at £214,000, of which £10,000 is held as an expendable endowment for the Dr last Memorial fund and £21,021 are restricted funds. The remaining £182,979 unrestricted funds are freely available to support the charitable objects.

Investments policy

The Society's investments are held in charity-specific low risk unit trusts and fixed interest securities.

Risk Mitigation

The trustees have reviewed the Society's exposure to major risks and have accordingly established that the Society's reserves are sufficient to mitigate them.

Structure, governance and management

The charitable company is a company limited by guarantee, and is incorporated in England. The company's registered address is 9 Bonhill Street, London, EC2A 4DJ.

The governing instrument is the Memorandum and Articles of Association (updated October 2021). The society is governed by a council of management, which consists of the Officers of the Society, the Chairmen of the Medical and Clinical Scientists Standing Committees, not more than eight ordinary members of the Council (being corporate members of the Society), and such corporate members of the Society (not exceeding three) as may be co-opted by Council at its discretion.

Trustees (Officers of the Society) are appointed in accordance with the Memorandum and Articles of Association. Persons are nominated for election as officers of the Society at least 6 weeks prior to the Annual General Meeting. If more than one person is nominated, a vote is taken at the AGM, otherwise the election is agreed by the council.

Newly appointed Officers are either already experienced in the role, or share duties and shadow the outgoing Officer.

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 30 JUNE 2024

A new role has been introduced which commenced in 2022 - President Elect - who will shadow the President for two years before serving a two-year term themselves as President.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Dr Zaloa Agirre-Arrizubieta	
Professor Mark Baker	
Dr Natalie Ross	
Dr Jacquie Deeb	(Resigned 6 October 2023)
Dr Sushma Goyal	
Dr Brython Hywel	
Dr Stephan Jaiser	
Dr Samantha Jefferson	
Professor Martin Koltzenburg	
Dr Andrew Michell	
Dr Friederike Moeller	
Dr Gareth Payne	
Dr Ronit Pressler	
Dr Syed Shah	
Dr Elisaveta Sokolov	(Resigned 6 October 2023)
Dr Rachel Thornton	
Dr Simon Freilich	(Appointed 6 October 2023)
Dr Jiten Mistry	(Appointed 6 October 2023)

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £2 in the event of a winding up.

The trustees' report was approved by the Board of Trustees.



Dr Gareth Payne

Trustee

Dated: 3rd October 2024

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

I report to the trustees on my examination of the financial statements of The British Society for Clinical Neurophysiology (the charitable company) for the year ended 30 June 2024.

Responsibilities and basis of report

As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charitable company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charitable company's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charitable company as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Katherine Dee FCA

Begbies Chartered Accountants
9 Bonhill Street
London
EC2A 4DJ

Dated: 30/10/24

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 30 JUNE 2024

Current financial year

	Notes	Unrestricted funds 2024 £	Restricted funds 2024 £	Endowment funds 2024 £	Total 2024 £	Total 2023 £
<u>Income from:</u>						
Donations and legacies	2	22,162	-	-	22,162	26,935
Charitable activities	3	37,203	-	-	37,203	34,300
Investments	4	5,167	1,244	-	6,411	4,153
Total income		64,532	1,244	-	65,776	65,388
<u>Expenditure on:</u>						
Charitable activities	5	67,199	487	-	67,686	46,866
Net gains/(losses) on investments	11	3,596	-	1,604	5,200	(4,640)
Net incoming resources before transfers		929	757	1,604	3,290	13,882
Gross transfers between funds		1,604	-	(1,604)	-	-
Net movement in funds		2,533	757	-	3,290	13,882
Fund balances at 1 July 2023		182,979	21,020	10,000	213,999	200,118
Fund balances at 30 June 2024		185,512	21,777	10,000	217,289	214,000

The statement of financial activities includes all gains and losses recognised in the year.

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

Prior financial year

		Unrestricted funds 2023 £	Restricted funds 2023 £	Endowment funds 2023 £	Total 2023 £
	Notes				
<u>Income from:</u>					
Donations and legacies	2	23,735	3,200	-	26,935
Charitable activities	3	34,300	-	-	34,300
Investments	4	2,945	1,208	-	4,153
Total income		60,980	4,408	-	65,388
<u>Expenditure on:</u>					
Charitable activities	5	44,153	2,713	-	46,866
Net gains/(losses) on investments	11	(3,490)	-	(1,150)	(4,640)
Net incoming resources before transfers		13,337	1,695	(1,150)	13,882
Gross transfers between funds		(1,150)	-	1,150	-
Net movement in funds		12,187	1,695	-	13,882
Fund balances at 1 July 2022		170,792	19,326	10,000	200,118
Fund balances at 30 June 2023		182,979	21,021	10,000	214,000

The statement of financial activities includes all gains and losses recognised in the year.

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

SUMMARY INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 JUNE 2024

	All income funds	
	2024	2023
	£	£
Gross income	65,776	65,388
Gains/(losses) on investments	3,596	(3,490)
Transfer from/(to) endowment funds	1,604	(1,150)
	<hr/>	<hr/>
Total income in the reporting period	70,976	60,748
	<hr/>	<hr/>
Total expenditure from income funds	67,686	46,866
	<hr/>	<hr/>
Net income for the year	3,290	13,882
	<hr/> <hr/>	<hr/> <hr/>

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

BALANCE SHEET

AS AT 30 JUNE 2024

	Notes	2024 £	£	2023 £	£
Fixed assets					
Investments	13		88,889		83,689
Current assets					
Debtors	14	916		894	
Cash at bank and in hand		138,903		132,696	
		139,819		133,590	
Creditors: amounts falling due within one year	16	(11,419)		(3,279)	
Net current assets			128,400		130,311
Net assets			217,289		214,000
The funds of the charitable company					
Endowment funds	17	10,000		10,000	
Restricted income funds	18	21,777		21,021	
Unrestricted funds		185,512		182,979	
		217,289		214,000	

For the year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.


The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 3rd October 2024



Professor Mark Baker

Company registration number 493724 (England and Wales)

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2024

1 Accounting policies

Charity information

The British Society for Clinical Neurophysiology is a private company limited by guarantee incorporated in England and Wales. The registered office is 9 Bonhill Street, London, EC2A 4DJ.

All of the trustees are members of the company and guarantee to contribute £2 in the event of a winding up.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charitable company's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charitable company is a Public Benefit Entity as defined by FRS 102.

The charitable company has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charitable company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

MSC Fund

The Medical Standing Committee fund was established from the residual reserves of the Association of British Clinical Neurophysiologists, which were donated during the year ended 30 June 2006. No travel expenses were reimbursed from this fund during the year.

The Christine and Adrian Fowle Prize Fund

This prize fund, established by past president of the society Adrian Fowle and his wife Christine is intended to recognise excellence in the practice of clinical neurophysiology other than in science, and in particular in its human aspects. £5,000 (plus £1,250 of gift aid) was donated to the Society in 2020.

Dr Last Memorial Fund

This expendable endowment fund was established by a generous donation from Dr Last's family and a contribution from the Society's reserves. Its purpose is to further the objectives of the Society, in particular in assisting younger members, by making grants to support foreign travel, enabling the recipient to visit laboratories where they may wish to learn new techniques or to plan or carry out joint research. It was not originally intended that funds should be used to facilitate attendance at conferences but it has been subsequently agreed that the fund may be used to finance bursaries. The fund originally comprised £10,000 of M & G Charifund units which yield an annual income and provides capital growth. During the year the investment generated investment income of £1,244. The committee will intend to distribute the annual income from the fund and may sell units to give additional finance provided that the market value of the capital invested in the fund does not fall below £10,000. It may make awards to one or more applicants or make no award if applicants are not considered suitable or if insufficient funds are available.

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

1 Accounting policies

(Continued)

1.4 Incoming resources

Incoming resources from charitable activities are recognised on an accruals basis. Investment income is received gross and accounted for on an accruals basis.

Cash donations are recognised on receipt. Membership fees are recorded as donations.

No provision has been made in these accounts for subscriptions unpaid at the end of the year. Subscriptions are recognised in full in the year in which they are received.

1.5 Resources expended

Resources expended are recognised in the year in which they are incurred. Support costs are those costs incurred in support of expenditure on the objects of the charity. Governance costs are those incurred in connection with compliance with constitutional and statutory requirements.

1.6 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8 Financial instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charitable company's balance sheet when the charitable company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charitable company's contractual obligations expire or are discharged or cancelled.

2 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Total
	2024 £	2024 £	2024 £	2023 £
ECCN grant	-	-	-	3,200
Membership fees	22,162	-	22,162	23,735
	<u>22,162</u>	<u>-</u>	<u>22,162</u>	<u>26,935</u>
For the year ended 30 June 2023	<u>23,735</u>	<u>3,200</u>		<u>26,935</u>

Donated goods and services

The Society were provided cost-free use of a meeting room for the 2022 Autumn Scientific Meeting. The fair value of this facility was measured at £3,000. No such equivalent was received in 2023.

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

3 Charitable activities

	2024 £	2023 £
Delegate fee income	17,003	19,550
Exhibitor fee income	20,200	14,750
	<u>37,203</u>	<u>34,300</u>
<i>Analysis by fund</i>		
Unrestricted funds	<u>37,203</u>	
For the year ended 30 June 2023		
Unrestricted funds		<u>34,300</u>
		<u>34,300</u>

Income from charitable activities consists of income from three scientific meetings (2023: three), and two courses.

4 Investments

	Unrestricted funds £	Restricted funds £	Total 2024 £	Total 2023 £
Income From Listed Investments	2,923	1,244	4,167	4,011
Bank Interest	2,244	-	2,244	142
	<u>5,167</u>	<u>1,244</u>	<u>6,411</u>	<u>4,153</u>
For the year ended 30 June 2023	<u>2,945</u>	<u>1,208</u>		<u>4,153</u>

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

5 Charitable activities

	Scientific Meetings	Grants and Awards	Total 2024	Total 2023
	£	£	£	£
Meeting costs	22,273	-	22,273	18,729
Other meeting costs	-	-	-	2,713
	<u>22,273</u>	<u>-</u>	<u>22,273</u>	<u>21,442</u>
Grant funding of activities (see note 6)	-	15,819	15,819	1,794
Share of support costs (see note 7)	24,198	-	24,198	20,497
Share of governance costs (see note 7)	5,396	-	5,396	3,133
	<u>51,867</u>	<u>15,819</u>	<u>67,686</u>	<u>46,866</u>
<u>Analysis by fund</u>				
Unrestricted funds	51,380	15,819	67,199	
Restricted funds	487	-	487	
	<u>51,867</u>	<u>15,819</u>	<u>67,686</u>	
For the year ended 30 June 2023				
Meeting costs	18,729	-		18,729
Other meeting costs	2,713	-		2,713
	<u>21,442</u>	<u>-</u>		<u>21,442</u>
Grant funding of activities (see note 6)	-	1,794		1,794
Share of support costs (see note 7)	20,497	-		20,497
Share of governance costs (see note 7)	3,133	-		3,133
	<u>45,072</u>	<u>1,794</u>		<u>46,866</u>
<u>Analysis by fund</u>				
Unrestricted funds	42,359	1,794		44,153
Restricted funds	2,713	-		2,713
	<u>45,072</u>	<u>1,794</u>		<u>46,866</u>

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

6 Grants payable

	2024 £	2023 £
Grants to individuals	15,819	1,794
	<u>15,819</u>	<u>1,794</u>
For the year ended 30 June 2023	<u>13,860</u>	

Grants and Awards

2024

General grants paid by the charitable company, consisting of the Adrian Prize for £1,000, the Christine and Adrian Fowle Prize Fund for £500, the Medical Student Essay Prize for £500, and 11 bursaries of £500 each (totalling £5,500) to reimburse trainees attending the EEG Course in Cambridge.

2023

General grants paid by the charitable company, consisting of the Grey Walter Medal, the Medical Student Essay Prize for £500 and a book bursary of £244.

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

7 Support costs

	Support costs	Governance costs	2024	2023
	£	£	£	£
Website	6,660	-	6,660	965
Clerical Assistance	15,451	-	15,451	16,673
Subscription - IFCN	1,149	-	1,149	1,227
Subscription - JNC	250	-	250	250
Bank charges	262	-	262	285
Sundry expenses	426	-	426	1,097
Examination fees	-	2,893	2,893	3,133
Legal and professional	-	2,265	2,265	-
Governance costs heading 1	-	238	238	-
	<u>24,198</u>	<u>5,396</u>	<u>29,594</u>	<u>23,630</u>
Analysed between				
Charitable activities	<u>24,198</u>	<u>5,396</u>	<u>29,594</u>	<u>23,630</u>

2023

All support costs are attributable to scientific meetings.

2022

Clerical Assistance consists of administration support, of which £1,482.35 can be directly attributable to the Teaching Course at Pembroke. Of the remaining administration support costs, based on time spent, 50% relates to meeting administration and 50% relates to non-meeting administration.

Computer costs totalling £296.71 can be directly attributable to the Teaching Course at Pembroke. The remaining support and governance costs have been allocated entirely to scientific meetings.

Governance costs includes accountants' fees of £3,113 (2023- £2,893) for examination fees.

8 Net movement in funds

	2024	2023
	£	£
The net movement in funds is stated after charging/(crediting):		
Fees payable for the independent examination of the charity's financial statements	<u>2,893</u>	<u>3,133</u>

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charitable company during the year (2022: £0). 3 trustees claimed travel expenses totalling £913 (2022: nil)

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

10 Employees

The average monthly number of employees during the year was:

	2024 Number	2023 Number
Total	-	-

There were no employees whose annual remuneration was more than £60,000.

Remuneration of key management personnel

The remuneration of key management personnel was as follows:

11 Gains and losses on investments

	Unrestricted funds 2024 £	Endowment funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Endowment funds 2023 £	Total 2023 £
Gains/(losses) arising on:						
Revaluation of investments	3,596	1,604	5,200	(3,490)	(1,150)	(4,640)

12 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

13 Fixed asset investments

	Listed investments £	Unlisted investments £	Total £
Cost or valuation			
At 1 July 2023	73,689	10,000	83,689
Valuation changes	5,200	-	5,200
At 30 June 2024	78,889	10,000	88,889
Carrying amount			
At 30 June 2024	78,889	10,000	88,889
At 30 June 2023	73,689	10,000	83,689

14 Debtors

	2024 £	2023 £
Amounts falling due within one year:		
Prepayments and accrued income	916	894

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

15 Loans and overdrafts

	2024 £	2023 £
Bank overdrafts	8,140	-
Payable within one year	8,140	-

16 Creditors: amounts falling due within one year

	Notes	2024 £	2023 £
Bank overdrafts	15	8,140	-
Accruals		3,279	3,279
		11,419	3,279

17 Endowment funds

Endowment funds represent assets which must be held permanently by the charitable company. Income arising on the endowment funds can be used in accordance with the objects of the charitable company and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.

	At 1 July 2023 £	Transfers £	Gains and losses £	At 30 June 2024 £
Permanent endowments	10,000	(1,604)	1,604	10,000
Previous year:	At 1 July 2022 £	Transfers £	Gains and losses £	At 30 June 2023 £
Permanent endowments	10,000	1,150	(1,150)	10,000

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

18 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 July 2023	Incoming resources	Resources expended	At 30 June 2024
	£	£	£	£
MSC Fund	12,006	-	-	12,006
Dr Last Memorial Fund	3,277	1,244	-	4,521
Christine and Adrian Fowle Prize Fund	5,250	-	-	5,250
Visit Britain ECCN grant	487	-	(487)	-
	<u>21,020</u>	<u>1,244</u>	<u>(487)</u>	<u>21,777</u>

Previous year:	At 1 July 2022	Incoming resources	Resources expended	At 30 June 2023
	£	£	£	£
MSC Fund	12,006	-	-	12,006
Dr Last Memorial Fund	2,070	1,208	-	3,278
Christine and Adrian Fowle Prize Fund	5,250	-	-	5,250
Visit Britain ECCN grant	-	3,200	(2,713)	487
	<u>19,326</u>	<u>4,408</u>	<u>(2,713)</u>	<u>21,021</u>

19 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 July 2023	Incoming resources	Resources expended	Transfers	Gains and losses	At 30 June 2024
	£	£	£	£	£	£
General funds	<u>182,979</u>	<u>64,532</u>	<u>(67,199)</u>	<u>1,604</u>	<u>3,596</u>	<u>185,512</u>
Previous year:	At 1 July 2022	Incoming resources	Resources expended	Transfers	Gains and losses	At 30 June 2023
	£	£	£	£	£	£
General funds	<u>170,792</u>	<u>60,980</u>	<u>(44,153)</u>	<u>(1,150)</u>	<u>(3,490)</u>	<u>182,979</u>

THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

20 Analysis of net assets between funds

	Unrestricted Fund £	Restricted Funds £	Endowment Fund £	Total £
Fund balances at 30 June 2024 are represented by:				
Investments	88,889	-	-	88,889
Current assets/(liabilities)	128,400	-	-	128,400
	<u>217,289</u>	<u>-</u>	<u>-</u>	<u>217,289</u>
	£	£	£	£
Fund balances at 30 June 2023 were represented by:				
Investments	83,689	-	-	83,689
Current assets/(liabilities)	109,778	20,533	-	130,311
	<u>193,467</u>	<u>20,533</u>	<u>-</u>	<u>214,000</u>

21 Related party transactions

There were no disclosable related party transactions during the year (2023 - none), other than the £500 Adrian & Christine Fowle Prize for 2022 being awarded to Dr J Bland.